|
Mickey,
I'm really glad to hear you have such a good relationship with your onc!
Your 'symptoms' could indeed be from something else, so let's say that you're 'asymptomatic' for now.
Ok, the fact that your other mets are limited to skin is a good thing, really. That usually translates as better prognosis and the docs will 'react' to that fact in offering treatment options for your brain mets.
I'm on a personalized dosage schedule of Temodar/Xeloda that my onc designed just for me. I'm 5" 4', 116 lbs; I take 250mg Temodar once @ night for 7 days (1/2 hr after dose of Zofran; 2hrs after eating). Simultaneously, I take 1000mg Xeloda 2x's day (tot+2000mg, just after food intake) for 14 days. Then two weeks off, not just one.
I also do 100mg of B-6 2x's da, lotion feet and hands, esp. at night. But truthfully, can't say I have side effects at all. My skin is very dry, I have days of low energy, complicated constipation while doing the Tem/Zofran...but QOL is very good and it's WINTER here when skin gets dry and it's too cold to get decent excersize!
I'd hope you could get two months of tx with this combo with a follow-up MRi before you begin the trial... I will add the small study report from San Antonio last yr...there might be something newer around now.
And I still don't understand exactly why additional focalized treatment is not being offered. As was in my case, I had lots of brain mets, but dealt with them in small batches over time. There are many others who have had combinations of WBR and multiple focalized tx's.
Mickey, do you visit the bcmets.org site? Doing a search on brain mets would bring you tons of supportive information.
I'm glad you'll have the opportunity to be in the Lapatinib trial. I will take that info to my onc at next appt.
Here's hoping for good response in which ever tx approach you pursue.
bighugs,
patty (and below is that report):
SABCS ABSTRACT:
[San Antonio Breast Cancer Symposium]
[1079] Phase I study of capecitabine (C) in combination with temozolomide (T) in the treatment of patients with brain metastases from breast carcinoma.
Rivera E, Valero V, Francis D, Brewster A, Royce M, Esteva F, Murray JL, Pusztai L, Hortobagyi GN.. The University of Texas M.D. Anderson Cancer Center, Houston, TX
Background: T is an oral alkylating agent that is
currently being used for the treatment of primary
brain tumors due to its ability to cross the
blood-brain barrier. C has been approved for use in
the treatment of metastatic breast cancer patients who
have failed anthracyclines and taxanes. It is well
known that C crosses the blood-brain barrier and has
activity in the brain. Options are limited for
patients with brain metastases.
Materials and Methods: We evaluated the activity of
both drugs in combination for the treatment of brain
metastases not amenable to surgery. Patients were
allowed in the study if they had new onset brain
metastases from breast cancer, had declined radiation
therapy, and were neurologically stable. They were
also eligible if they had evidence of recurrence or
progression of brain metastases after whole brain or
stereotactic radiation therapy. C was started at 1800
mg/m2 in 2 divided doses. T was given at a starting
dose of 75 mg/m2 in one daily dose. Each drug was
given concomitantly every day for 5 days (day 1-5)
followed by 2 days of rest and restarted again for an
additional 5 days (days 8-12). Each cycle was repeated
every 21 days. We have enrolled a total of 16 pts — 6
pts at dose level 0 (C/T — 1800/75), 6 pts at dose
level 1 (C/T — 1800/100), and 4 pts at dose level 2
(C/T — 2000/100).
Results: Five pts had recurrent brain metastases and
had been previously treated with radiation therapy.
The median age is 51 yrs (range, 32-77). All pts had a
Zubrod performance status < 1. Ten pts were ER and/or
PR positive. No grade 4 toxicities have been reported.
Grade 3 toxicity includes headaches (2 pts), vomiting
(1 pt), constipation (2 pts), fatigue (2 pts),
nonneutropenic fever (1 pt). We have observed 1 CR, 1
PR, 6 MR, and 3 SD. Four pts did not respond to
treatment. One pt was not evaluable for response.
Median duration of response in brain was 10.5 weeks
(range, 6-48+ wks). Two pts with SD and 2 pts with MR
had previously received whole brain radiation therapy.
Three pts were taken off the study because of
progression of disease outside the brain including the
pt who had a CR in brain but progressed systemically.
Four pts are actively being treated in the study.
(me would equal: 2808-3120 Xeloda & 117-156 Temodar / currently on 2000 Xeloda & 250 Temodar)
Conclusions: The combination of C and T seems to be
active and well tolerated for the treatment of brain
metastases from breast carcinoma. Further studies
should include the evaluation of this combination with
radiation and as adjuvant therapy in those pts who are
at high risk of developing brain metastases.
Wednesday, December 8, 2004 4:30 PM
|